Mon, May
62 New Articles

Turunc and Aksan Advise on PhiTech Investment Round

Turunc and Aksan Advise on PhiTech Investment Round

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Turunc has advised the Future Impact Fund on its investment in precision medicine biotechnology company PhiTech Bioinformatics. The Aksan law firm advised PhiTech on the Maxis Arya Venture Capital Fund-led investment round.

According to Aksan, PhiTech is a health biotech company "providing innovative AI-powered clinical decision support software for the molecular diagnostics of rare genetic diseases through a multi-omics approach, utilizing DNA and RNA sequencing data for more precise and faster diagnosis."

According to Turunc, Gelecek Etki Fonu (the Future Impact Fund) is a capital markets board-regulated venture capital fund managed jointly by Tacirler Asset Management, an asset management company, and Vestel Ventures, the corporate venture capital arm of Vestel, one of the largest home appliances companies in Turkiye and a group company of Zorlu Holding, a Turkish conglomerate.

The Turunc team included Managing Partner Kerem Turunc, Partner Esin Camlibel, and Associates Naz Esen, Beste Yildizili Ergul, Ovgu Kopal, Canberk Taze, and Batuhan Eraslan.

The Aksan team included Partner Alper Onar, Senior Associate Merve Kutukcuoglu Karpuzcu, and Associate Nihan Kul.